Familial amyloidosis diagnostic study of choice

Jump to navigation Jump to search

Familial amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Familial amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Familial amyloidosis diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Familial amyloidosis diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Familial amyloidosis diagnostic study of choice

CDC on Familial amyloidosis diagnostic study of choice

Familial amyloidosis diagnostic study of choice in the news

Blogs on Familial amyloidosis diagnostic study of choice

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Familial amyloidosis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Tissue biopsy with Congo red stain is the gold standard test for the diagnosis of amyloidosis. Biopsy may be taken from an affected organ such as kidney, or from subcutaneous fat or rectal mucosa. There are no established criteria for the diagnosis of familial amyloidosis.

Diagnostic Study of Choice

Study of choice

Diagnostic Results

The following finding on tissue biopsy is confirmatory for familial amyloidosis:[3][4]

Sequence of Diagnostic Studies

The various investigations must be performed in the following order:

Name of Diagnostic Criteria

There are no established criteria for the diagnosis of familial amyloidosis.

References

  1. Benson MD, Yazaki M, Magy N (December 2002). "Laboratory assessment of transthyretin amyloidosis". Clin. Chem. Lab. Med. 40 (12): 1262–5. doi:10.1515/CCLM.2002.218. PMID 12553428.
  2. Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA (December 2002). "Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy". Mayo Clin. Proc. 77 (12): 1287–90. doi:10.4065/77.12.1287. PMID 12479513.
  3. COHEN AS, CALKINS E (April 1959). "Electron microscopic observations on a fibrous component in amyloid of diverse origins". Nature. 183 (4669): 1202–3. doi:10.1038/1831202a0. PMID 13657054.
  4. Kyle RA (September 2001). "Amyloidosis: a convoluted story". Br. J. Haematol. 114 (3): 529–38. doi:10.1046/j.1365-2141.2001.02999.x. PMID 11552976.

Template:WH Template:WS